Ashkon Software



CERU - Cerulean Pharma Inc.

Cerulean Pharma Inc. logo Cerulean Pharma Inc. (CERU) was a clinical stage company that focused on the development of nanoparticle-drug conjugates (NDCs) to treat cancer. The company's proprietary technology platform utilized nanotechnology to create small, spherical particles that were designed to deliver therapeutic payloads to tumors. The NDCs were engineered to be taken up selectively by cancer cells and to release their therapeutic payloads in a controlled manner, thereby reducing toxicity to healthy tissue.

Cerulean's lead product candidate, CRLX101, was a NDC that delivered the chemotherapeutic agent camptothecin. The company conducted clinical trials of CRLX101 in a variety of cancer indications, including ovarian cancer, renal cell carcinoma, and non-small cell lung cancer. In July 2017, Cerulean announced that it had discontinued development of CRLX101 and was exploring strategic alternatives, including the potential sale of the company.

In addition to CRLX101, Cerulean had a pipeline of other NDC candidates in preclinical development. These included CRLX301, which was designed to deliver the chemotherapeutic agent docetaxel, and CRLX121, which was designed to deliver the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax.

Cerulean was founded in 2005 and was headquartered in Waltham, Massachusetts. The company was publicly traded on the NASDAQ exchange under the ticker s




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer